open access

Vol 26, No 1 (2019)
POSITION PAPER
Submitted: 2019-03-07
Accepted: 2019-03-07
Published online: 2019-03-14
Get Citation

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society

Łukasz Kołtowski1, Jacek Legutko2, Krzysztof J. Filipiak1, Artur Dziewierz3, Stanisław Bartuś4, Paweł Buszman45, Piotr Buszman67, Dariusz Ciećwierz8, Maciej Dąbrowski9, Sławomir Dobrzycki10, Robert Gil11, Jarosław Gorący12, Marek Grygier13, Miłosz Jaguszewski8, Janusz Kochman1, Jacek Kubica14, Wiktor Kuliczkowki15, Piotr Lodziński1, Andrzej Ochała16, Krzysztof Reczuch17, Adam Witkowski9, Wojciech Wojakowski18, Jarosław Wójcik19, Dariusz Dudek2021
DOI: 10.5603/CJ.2019.0029
·
Pubmed: 30882184
·
Cardiol J 2019;26(1):1-7.
Affiliations
  1. 1st Department of Cardiology, Medical University of Warsaw, Poland
  2. Department of Interventional Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland
  3. 2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
  4. Department of Epidemiology and Statistics. Medical School of Silesia, Katowice, Poland
  5. Department of Cardiovascular Research, American Heart of Poland, Ustron, Poland
  6. Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland
  7. Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
  8. 1st Department of Cardiology, Medical University of Gdansk, Poland
  9. Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
  10. Department of Invasive Cardiology, Medical University of Bialystok, Poland
  11. Department of Invasive Cardiology of the Center of Postgraduate Medical Education, Central Hospital of the Internal Affairs Ministry and Administration, Warsaw, Poland
  12. Department of Cardiology, Pomeranian Medical University, Szczecin, Poland
  13. Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
  14. Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
  15. Department and Clinic of Cardiology, Wroclaw Medical University, Wroclaw, Poland
  16. Invasive Cardiology and Electrocardiology Department, Medical University of Silesia, Katowice Poland
  17. Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland
  18. Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
  19. “IKARDIA” Hospital of Invasive Cardiology, Naleczow, Poland
  20. 2nd Department of Clinical Cardiology and Cardiovascular Interventions, Jagiellonian University Hospital, Krakow, Poland
  21. Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

open access

Vol 26, No 1 (2019)
POSITION PAPER
Submitted: 2019-03-07
Accepted: 2019-03-07
Published online: 2019-03-14

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society

Journal

Cardiology Journal

Issue

Vol 26, No 1 (2019)

Pages

1-7

Published online

2019-03-14

Page views

2742

Article views/downloads

1470

DOI

10.5603/CJ.2019.0029

Pubmed

30882184

Bibliographic record

Cardiol J 2019;26(1):1-7.

Authors

Łukasz Kołtowski
Jacek Legutko
Krzysztof J. Filipiak
Artur Dziewierz
Stanisław Bartuś
Paweł Buszman
Piotr Buszman
Dariusz Ciećwierz
Maciej Dąbrowski
Sławomir Dobrzycki
Robert Gil
Jarosław Gorący
Marek Grygier
Miłosz Jaguszewski
Janusz Kochman
Jacek Kubica
Wiktor Kuliczkowki
Piotr Lodziński
Andrzej Ochała
Krzysztof Reczuch
Adam Witkowski
Wojciech Wojakowski
Jarosław Wójcik
Dariusz Dudek

References (26)
  1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.
  2. Wożakowska-Kapłon B, Lesiak M, Ochała A, et al. [Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the Polish Cardiac Society]. Kardiol Pol. 2014; 72(8): 761–765.
  3. Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018; 392(10150): 835–848.
  4. Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019; 93(2): 241–247.
  5. Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 10(6): 3341–3360.
  6. Grajek S, Michalak M, Gwizdała A, et al. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiol Pol. 2018; 76(4): 740–749.
  7. Neumann F-J, Ahlsson A, Alfonso F, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 34(10): 2949.
  8. Kereiakes D, Yeh R, Massaro J, et al. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC: Cardiovasc Interv. 2015; 8(12): 1552–1562.
  9. Kam PCA, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005; 60(6): 565–574.
  10. Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013; 1(2): 83–97.
  11. Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993; 71(10): 778–782.
  12. Stratmann G, deSilva A, Tseng E, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004: 1635–1639.
  13. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015; 373(11): 997–1009.
  14. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017; 377(12): 1132–1142.
  15. Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus. Kardiol Pol. 2019 [Epub ahead of print].
  16. Mallifi JR, Lotfi AS. Management of STEMI in Patients on NOACs and Undergoing Primary PCI. Expert Analysis ACC website 2015. https://www.acc.org/latest-in-cardiology/articles/2015/10/22/10/43/management-of-stemi-in-patients-on-noacs-and-undergoing-primary-pci.
  17. Wojtasik-Bakalarz J, Kleczyński P, Zasada W, et al. Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up. Advances in Inverventional Cardiology. .
  18. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012; 307(17): 1817–1826.
  19. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358(21): 2218–2230.
  20. Stone G, McLaurin B, Cox D, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21): 2203–2216.
  21. Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23): 2207–2217.
  22. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
  23. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
  24. Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018; 128(2): 390–400.
  25. Schwenkglenks M, Brazier JE, Szucs TD, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011; 14(1): 24–33.
  26. Borg S, Persson U, Allikmets K, et al. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther. 2006; 28(11): 1947–1959.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl